Lim CC, et al. - The epidemiology, risk factors and outcomes of cytomegalovirus (CMV) infection were ascertained among patients with glomerulonephritis (GN) who received potent immunosuppressants (IS) via performing a single-centre retrospective study of adults with biopsy-proven GN prescribed methylprednisolone (MP), cyclophosphamide (CYC) or rituximab (RTX). Observations suggested a common prevalence of CMV infection in GN patients receiving potent IS. They recommend considering surveillance and possibly anti-viral prophylaxis for high-risk patients.